Glucotrack Inc (GCTK)

$0.28 0.00 (-1.47%)
Market Cap 2.18M
Revenue (ttm) 0.00
Net Income (ttm) -19.39M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -1.11
Volume 2,680,100
Avg Vol 13,869,550
Day's Range N/A - N/A
Shares Out 7.72M
Stochastic %K 3%
Beta 0.70
Analysts Strong Buy
Price Target N/A

Company Profile

GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 200...

Industry: Medical Devices
Sector: Healthcare
Phone: 201 842 7715
Address:
301 Route 17 North, Suite 800, Rutherford, United States
PSM_EmpowerTrading
PSM_EmpowerTrading Aug. 31 at 3:24 AM
🌅 Watchlist part 2 ✅ $WETO low 7 support, above 7.20, potential to 8/8.70 🔄 $VBIO 1/25 reverse split (RS), new price ~3 🔄 $OMH 1/50 RS, new price ~3.50 🔄 $NXL 1/30 RS, new price ~7.50 🔄 $GCTK 1/15 RS, new price ~4.23 ✅ Ideal long entry near current support 🎯 Ideal stop loss below current support 🚨 Avoid chasing longs into strength near resistance 🎯🎯 Goal is GREEN 🤑🤑 not GREED 🥵🥵
0 · Reply
HMIC
HMIC Aug. 30 at 1:16 AM
$GCTK The Tutes will be jumping on board.
0 · Reply
BullishCandle
BullishCandle Aug. 29 at 10:57 PM
$GCTK $INHD Everyone is ignoring the best setup for next week. NCRA has the recipe to see a parabolic move. Market is slowly finding this low float gem. Has everything, Bullish DD/ low float/ and a strong close. If you like money, make sure to put NCRA on watch!
0 · Reply
PrimetimeVibes
PrimetimeVibes Aug. 29 at 6:30 AM
$NCRA What started as a strategic investment is becoming part of a much bigger story. 💎NCRA is advancing its transformation into Nocera Holdings, with a vision built around multiple high-growth technology markets spanning AI, digital infrastructure, robotics, biotech and digital assets. Parabolic potential here on NCRA, don't miss out. $SLGB $BTAI $SUGP $GCTK
0 · Reply
HMIC
HMIC Aug. 29 at 2:29 AM
$GCTK Looks like the price post split will be 4.20.
0 · Reply
focafoca99
focafoca99 Aug. 28 at 10:57 PM
$GCTK executed a 1-for-15 reverse stock split, consolidating shares and adjusting the share count.
0 · Reply
Adubstradesmini
Adubstradesmini Aug. 28 at 9:18 PM
$ARTL $CALC $CHGA $FTFT $GCTK
0 · Reply
itsStocksOver
itsStocksOver Aug. 28 at 8:45 PM
$GCTK buy orders at 0.21
0 · Reply
TwongStocks
TwongStocks Aug. 28 at 8:10 PM
Tracking a total of 10 stocks with reverse splits on Monday. Nine on NASDAQ and one on the NYSE American. Expect trading to halt at 7:50pm ET tonight and resume at 9:00am Monday morning. I'll have to split the summary into two parts. Part 1 of 2: $ARTL 1 for 9. Will reduce outstanding shares from approx 4.93m to approx 548k. $CALC 1 for 5. Will reduce outstanding shares from approx 34.5m to approx 6.9m. $CHGA 1 for 20. Will reduce outstanding shares from approx 21.1m to approx 1.05m. $FTFT 1 for 4. Will reduce outstanding shares from approx 32.31m to approx 8.08m. $GCTK 1 for 15. Will reduce outstanding shares from approx 11.97m to approx 798k.
0 · Reply
OG80
OG80 Aug. 28 at 4:16 PM
$GCTK liquidate me. holding. fuck em.
0 · Reply
Latest News on GCTK
GlucoTrack Inc trading halted, news pending

2026-08-28T23:55:29.000Z - 2 days ago

GlucoTrack Inc trading halted, news pending

GlucoTrack announces 1-for-15 reverse stock split

2026-08-27T12:06:14.000Z - 3 days ago

GlucoTrack announces 1-for-15 reverse stock split

Glucotrack, Inc. Announces Reverse Stock Split

Aug 27, 2026, 8:00 AM EDT - 3 days ago

Glucotrack, Inc. Announces Reverse Stock Split

GlucoTrack subsidiary initiates clinical trial manufacturing for LT-100

2026-08-25T12:15:16.000Z - 5 days ago

GlucoTrack subsidiary initiates clinical trial manufacturing for LT-100

Lokahi expands ai2 Future Labs asset origination netowrk

2026-08-21T12:05:14.000Z - 9 days ago

Lokahi expands ai2 Future Labs asset origination netowrk

GlucoTrack Proxy statement: Proxy filing

Aug 21, 2026, 8:00 AM EDT - 9 days ago

GlucoTrack Proxy statement: Proxy filing

GlucoTrack Transcript: AGM 2026

Aug 18, 2026, 12:00 PM EDT - 12 days ago

GlucoTrack Transcript: AGM 2026

GlucoTrack achieves key compliance milestone

2026-08-17T12:11:08.000Z - 13 days ago

GlucoTrack achieves key compliance milestone

Glucotrack Achieves Key Compliance Milestone and Advances Strategic Transformation

Aug 17, 2026, 8:00 AM EDT - 13 days ago

Glucotrack Achieves Key Compliance Milestone and Advances Strategic Transformation

GlucoTrack Quarterly report: Q2 2026

Aug 14, 2026, 7:00 AM EDT - 16 days ago

GlucoTrack Quarterly report: Q2 2026

GlucoTrack Proxy statement: Proxy filing

Aug 10, 2026, 8:00 AM EDT - 20 days ago

GlucoTrack Proxy statement: Proxy filing

E.F. Hutton & Co. Acts as Exclusive Financial Advisor for $5.5 Million Financing for Glucotrack

Aug 6, 2026, 8:15 AM EDT - 24 days ago

E.F. Hutton & Co. Acts as Exclusive Financial Advisor for $5.5 Million Financing for Glucotrack

GlucoTrack announces $5.5M financing

2026-08-05T14:14:16.000Z - 25 days ago

GlucoTrack announces $5.5M financing

Glucotrack Announces $5.5 Million Financing

Aug 5, 2026, 8:30 AM EDT - 25 days ago

Glucotrack Announces $5.5 Million Financing

GlucoTrack announces expansion of ai Futures Lab

2026-07-31T12:16:28.000Z - 4 weeks ago

GlucoTrack announces expansion of ai Futures Lab

Lōkahi Therapeutics™ ai² Futures Lab™ Changes How Biopharma Builds a Pipeline

Jul 31, 2026, 8:00 AM EDT - 4 weeks ago

Lōkahi Therapeutics™ ai² Futures Lab™ Changes How Biopharma Builds a Pipeline

GlucoTrack Proxy statement: Proxy filing

Jul 31, 2026, 8:00 AM EDT - 4 weeks ago

GlucoTrack Proxy statement: Proxy filing

Lōkahi Therapeutics™ Advances LT-100 Development Strategy Toward Single-Injection Administration

Jul 29, 2026, 5:30 PM EDT - 4 weeks ago

Lōkahi Therapeutics™ Advances LT-100 Development Strategy Toward Single-Injection Administration

E.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million Convertible Note Financing

Jul 17, 2026, 1:20 PM EDT - 6 weeks ago

E.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million Convertible Note Financing

Glucotrack, Inc. and Lōkahi Therapeutics™ Announce Strategic Financing Support from E.F. Hutton & Co. in Connection with Their Recently Completed Business Combination and Future Capital Markets Initiatives

Jul 17, 2026, 8:05 AM EDT - 6 weeks ago

Glucotrack, Inc. and Lōkahi Therapeutics™ Announce Strategic Financing Support from E.F. Hutton & Co. in Connection with Their Recently Completed Business Combination and Future Capital Markets Initiatives

GlucoTrack Proxy statement: Proxy filing

Jul 17, 2026, 8:00 AM EDT - 6 weeks ago

GlucoTrack Proxy statement: Proxy filing

UPDATE – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform

Jul 16, 2026, 4:57 PM EDT - 6 weeks ago

UPDATE – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform

Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform

Jul 14, 2026, 5:40 PM EDT - 6 weeks ago

Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform

GlucoTrack announces USPTO notice of allowance for patent application

2026-07-08T12:16:14.000Z - 7 weeks ago

GlucoTrack announces USPTO notice of allowance for patent application

Glucotrack Announces USPTO Notice of Allowance for Patent Application Covering Its Implantable CBGM Platform

Jul 8, 2026, 8:00 AM EDT - 7 weeks ago

Glucotrack Announces USPTO Notice of Allowance for Patent Application Covering Its Implantable CBGM Platform

GlucoTrack Proxy statement: Proxy filing

Jun 17, 2026, 8:00 AM EDT - 2 months ago

GlucoTrack Proxy statement: Proxy filing

Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association's 2026 Scientific Sessions

May 26, 2026, 8:00 AM EDT - 3 months ago

Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association's 2026 Scientific Sessions

Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

May 14, 2026, 5:27 PM EDT - 3 months ago

Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

GlucoTrack Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 3 months ago

GlucoTrack Quarterly report: Q1 2026

GlucoTrack Earnings release: Q1 2026

May 14, 2026, 7:00 AM EDT - 3 months ago

GlucoTrack Earnings release: Q1 2026

GlucoTrack submits IDE application to initiate study for CBGM technology

2026-05-07T17:06:12.000Z - 4 months ago

GlucoTrack submits IDE application to initiate study for CBGM technology

Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology

May 7, 2026, 1:00 PM EDT - 4 months ago

Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology

GlucoTrack Slides: Investor presentation

May 5, 2026, 7:00 AM EDT - 4 months ago

GlucoTrack Slides: Investor presentation

Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology

Apr 30, 2026, 9:00 AM EDT - 4 months ago

Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology

GlucoTrack announces publication of peer-reviewed article on glucose sensors

2026-04-21T13:32:23.000Z - 4 months ago

GlucoTrack announces publication of peer-reviewed article on glucose sensors

Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology

Apr 21, 2026, 8:00 AM EDT - 4 months ago

Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology

Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Mar 30, 2026, 4:50 PM EDT - 5 months ago

Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

GlucoTrack Earnings release: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 5 months ago

GlucoTrack Earnings release: Q4 2025

GlucoTrack Annual report: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 5 months ago

GlucoTrack Annual report: Q4 2025

Why is Glucotrack Stock (GCTK) Up Nearly 30% Today?

2026-03-27T13:29:54.000Z - 5 months ago

Why is Glucotrack Stock (GCTK) Up Nearly 30% Today?

GlucoTrack to file IDE to FDA for continuous blood glucose monitoring technology

2026-03-27T12:34:29.000Z - 5 months ago

GlucoTrack to file IDE to FDA for continuous blood glucose monitoring technology

Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones

Mar 27, 2026, 8:01 AM EDT - 5 months ago

Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones

GlucoTrack Transcript: EGM 2026

Mar 12, 2026, 11:00 AM EDT - 6 months ago

GlucoTrack Transcript: EGM 2026

Glucotrack to Present at LSI USA '26 Medtech Innovation Summit

Mar 10, 2026, 8:01 AM EDT - 6 months ago

Glucotrack to Present at LSI USA '26 Medtech Innovation Summit

GlucoTrack Proxy statement: Proxy Filing

Feb 9, 2026, 7:00 AM EST - 7 months ago

GlucoTrack Proxy statement: Proxy Filing

GlucoTrack announces USPTO approval for issuance of patents for CBGM platform

2026-01-29T13:10:24.000Z - 7 months ago

GlucoTrack announces USPTO approval for issuance of patents for CBGM platform

Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform

Jan 29, 2026, 8:01 AM EST - 7 months ago

Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform

GlucoTrack Proxy statement: Proxy Filing

Jan 29, 2026, 7:00 AM EST - 7 months ago

GlucoTrack Proxy statement: Proxy Filing

GlucoTrack files to sell 3.22M shares of common stock for holders

2026-01-13T21:10:53.000Z - 8 months ago

GlucoTrack files to sell 3.22M shares of common stock for holders

GlucoTrack Registration statement: Registration Filing

Jan 13, 2026, 7:00 AM EST - 8 months ago

GlucoTrack Registration statement: Registration Filing

GlucoTrack prices 1.03M shares at $3.87 in private placement

2025-12-30T13:05:37.000Z - 8 months ago

GlucoTrack prices 1.03M shares at $3.87 in private placement

Glucotrack, Inc. Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Institutional Investor

Dec 30, 2025, 8:00 AM EST - 8 months ago

Glucotrack, Inc. Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Institutional Investor

Glucotrack Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate Highlights

Nov 13, 2025, 4:05 PM EST - 10 months ago

Glucotrack Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate Highlights

GlucoTrack Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 10 months ago

GlucoTrack Earnings release: Q3 2025

GlucoTrack Quarterly report: Q3 2025

Nov 13, 2025, 7:00 AM EST - 10 months ago

GlucoTrack Quarterly report: Q3 2025

GlucoTrack Transcript: AGM 2025

Nov 7, 2025, 12:00 PM EST - 10 months ago

GlucoTrack Transcript: AGM 2025

GlucoTrack Proxy statement: Proxy Filing

Nov 7, 2025, 7:00 AM EST - 10 months ago

GlucoTrack Proxy statement: Proxy Filing

Glucotrack, Inc. Encourages Shareholders to Vote

Nov 3, 2025, 4:05 PM EST - 10 months ago

Glucotrack, Inc. Encourages Shareholders to Vote

GlucoTrack Proxy statement: Proxy Filing

Nov 3, 2025, 7:00 AM EST - 10 months ago

GlucoTrack Proxy statement: Proxy Filing

GlucoTrack Proxy statement: Proxy Filing

Oct 31, 2025, 8:00 AM EDT - 10 months ago

GlucoTrack Proxy statement: Proxy Filing

Glucotrack Appoints Neuromodulation and Painful Diabetic Neuropathy Expert, Usman Latif, MD, MBA, to Clinical Advisory Team

Oct 29, 2025, 4:05 PM EDT - 10 months ago

Glucotrack Appoints Neuromodulation and Painful Diabetic Neuropathy Expert, Usman Latif, MD, MBA, to Clinical Advisory Team

GlucoTrack Inc trading resumes

2025-10-29T13:41:17.000Z - 10 months ago

GlucoTrack Inc trading resumes

GlucoTrack Inc trading halted, volatility trading pause

2025-10-29T13:36:24.000Z - 10 months ago

GlucoTrack Inc trading halted, volatility trading pause

GlucoTrack reminds shareholders to vote on equity purchase agreement

2025-10-28T12:21:41.000Z - 10 months ago

GlucoTrack reminds shareholders to vote on equity purchase agreement

Glucotrack, Inc. Reminds Shareholders to Vote

Oct 28, 2025, 8:00 AM EDT - 10 months ago

Glucotrack, Inc. Reminds Shareholders to Vote

GlucoTrack Proxy statement: Proxy Filing

Oct 28, 2025, 8:00 AM EDT - 10 months ago

GlucoTrack Proxy statement: Proxy Filing

GlucoTrack Proxy statement: Proxy Filing

Oct 15, 2025, 8:00 AM EDT - 11 months ago

GlucoTrack Proxy statement: Proxy Filing

GlucoTrack Registration statement: Registration Filing

Oct 8, 2025, 8:00 AM EDT - 11 months ago

GlucoTrack Registration statement: Registration Filing

GlucoTrack Proxy statement: Proxy Filing

Oct 3, 2025, 8:00 AM EDT - 11 months ago

GlucoTrack Proxy statement: Proxy Filing

GlucoTrack files to sell 20.06M shares of common stock for holders

2025-09-29T21:15:08.000Z - 11 months ago

GlucoTrack files to sell 20.06M shares of common stock for holders

GlucoTrack Registration statement: Registration Filing

Sep 29, 2025, 8:00 AM EDT - 11 months ago

GlucoTrack Registration statement: Registration Filing

GlucoTrack Proxy statement: Proxy Filing

Sep 23, 2025, 8:00 AM EDT - 1 year ago

GlucoTrack Proxy statement: Proxy Filing

GlucoTrack Transcript: Q3 Investor Summit Group Virtual Conference 2025

Sep 16, 2025, 1:30 PM EDT - 1 year ago

GlucoTrack Transcript: Q3 Investor Summit Group Virtual Conference 2025

Glucotrack to Participate in the Q3 Virtual Investor Summit

Sep 11, 2025, 8:00 AM EDT - 1 year ago

Glucotrack to Participate in the Q3 Virtual Investor Summit

Glucotrack Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Aug 14, 2025, 4:05 PM EDT - 1 year ago

Glucotrack Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

GlucoTrack Earnings release: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 1 year ago

GlucoTrack Earnings release: Q2 2025

GlucoTrack Quarterly report: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 1 year ago

GlucoTrack Quarterly report: Q2 2025

Glucotrack Expands Clinical Advisory Team Appointing David S. Hirsh, MD as Medical Director, Cardiology

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Glucotrack Expands Clinical Advisory Team Appointing David S. Hirsh, MD as Medical Director, Cardiology

Glucotrack to Exhibit at 2025 Association of Diabetes Care and Education Specialists Annual Meeting

Jul 31, 2025, 8:30 AM EDT - 1 year ago

Glucotrack to Exhibit at 2025 Association of Diabetes Care and Education Specialists Annual Meeting

Glucotrack Announces Repurchase of Series A Warrants

Jul 8, 2025, 8:30 AM EDT - 1 year ago

Glucotrack Announces Repurchase of Series A Warrants

Glucotrack and OneTwo Analytics Present Positive Final Results of First-In-Human Study for Continuous Blood Glucose Monitor at American Diabetes Association's 85th Scientific Sessions

Jun 25, 2025, 8:30 AM EDT - 1 year ago

Glucotrack and OneTwo Analytics Present Positive Final Results of First-In-Human Study for Continuous Blood Glucose Monitor at American Diabetes Association's 85th Scientific Sessions

Glucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing Requirements

Jun 12, 2025, 9:05 AM EDT - 1 year ago

Glucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing Requirements

Glucotrack to Showcase Long-Term Continuous Blood Glucose Monitor at American Diabetes Association's 85th Scientific Sessions

Jun 4, 2025, 8:30 AM EDT - 1 year ago

Glucotrack to Showcase Long-Term Continuous Blood Glucose Monitor at American Diabetes Association's 85th Scientific Sessions

Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD

May 28, 2025, 8:30 AM EDT - 1 year ago

Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD

Glucotrack Establishes Patient Advisory Board to Inform Diabetes Technology Development

May 20, 2025, 8:30 AM EDT - 1 year ago

Glucotrack Establishes Patient Advisory Board to Inform Diabetes Technology Development

Glucotrack Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 14, 2025, 5:10 PM EDT - 1 year ago

Glucotrack Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

GlucoTrack Quarterly report: Q1 2025

May 14, 2025, 4:00 PM EDT - 1 year ago

GlucoTrack Quarterly report: Q1 2025

GlucoTrack Earnings release: Q1 2025

May 14, 2025, 4:00 PM EDT - 1 year ago

GlucoTrack Earnings release: Q1 2025

Glucotrack Announces Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor

May 13, 2025, 8:01 AM EDT - 1 year ago

Glucotrack Announces Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor

GlucoTrack Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

GlucoTrack Proxy statement: Proxy Filing

GlucoTrack Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

GlucoTrack Proxy statement: Proxy Filing

Glucotrack to Participate in FORGETDIABETES, a Prominent European Research Initiative to Develop a Bionic Pancreas

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Glucotrack to Participate in FORGETDIABETES, a Prominent European Research Initiative to Develop a Bionic Pancreas

Glucotrack and OneTwo Analytics to Collaborate for Clinical Study Analysis on Its Continuous Blood Glucose Monitor

Apr 3, 2025, 8:01 AM EDT - 1 year ago

Glucotrack and OneTwo Analytics to Collaborate for Clinical Study Analysis on Its Continuous Blood Glucose Monitor

Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights

Mar 31, 2025, 5:00 PM EDT - 1 year ago

Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights

GlucoTrack Annual report: Q4 2024

Mar 31, 2025, 5:00 PM EDT - 1 year ago

GlucoTrack Annual report: Q4 2024

GlucoTrack Earnings release: Q4 2024

Mar 31, 2025, 5:00 PM EDT - 1 year ago

GlucoTrack Earnings release: Q4 2024

Glucotrack to Present First-In-Human Study Results for Continuous Blood Glucose Monitor at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes

Mar 19, 2025, 8:01 AM EDT - 1 year ago

Glucotrack to Present First-In-Human Study Results for Continuous Blood Glucose Monitor at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes

Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board Member

Feb 26, 2025, 8:01 AM EST - 1 year ago

Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board Member

Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering

Feb 4, 2025, 12:24 PM EST - 1 year ago

Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering

Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor

Feb 4, 2025, 8:01 AM EST - 1 year ago

Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor

Glucotrack Strengthens Leadership Team with Appointment of New Chief Financial Officer

Jan 29, 2025, 9:00 AM EST - 1 year ago

Glucotrack Strengthens Leadership Team with Appointment of New Chief Financial Officer

Glucotrack Announces ISO 13485:2016 Certification

Jan 21, 2025, 8:01 AM EST - 1 year ago

Glucotrack Announces ISO 13485:2016 Certification

Glucotrack Strenghtens Leadership Team with Addition of Industry Veteran as Vice President of Regulatory Affairs

Jan 15, 2025, 8:01 AM EST - 1 year ago

Glucotrack Strenghtens Leadership Team with Addition of Industry Veteran as Vice President of Regulatory Affairs

Glucotrack to Present at TechBio Showcase™ 2025

Jan 7, 2025, 4:05 PM EST - 1 year ago

Glucotrack to Present at TechBio Showcase™ 2025

GlucoTrack Proxy statement: Proxy Filing

Dec 6, 2024, 7:00 AM EST - 1 year ago

GlucoTrack Proxy statement: Proxy Filing

GLUCOTRACK ANNOUNCES START OF ENROLLMENT FOR HUMAN CLINICAL STUDY OF CONTINUOUS BLOOD GLUCOSE MONITOR

Dec 3, 2024, 8:30 AM EST - 1 year ago

GLUCOTRACK ANNOUNCES START OF ENROLLMENT FOR HUMAN CLINICAL STUDY OF CONTINUOUS BLOOD GLUCOSE MONITOR

GlucoTrack Proxy statement: Proxy Filing

Nov 22, 2024, 7:00 AM EST - 1 year ago

GlucoTrack Proxy statement: Proxy Filing

Glucotrack, Inc. Announces Closing of $10.0 Million Public Offering and Concurrent Private Placement Converting $4.0 in Outstanding Debt

Nov 14, 2024, 4:30 PM EST - 1 year ago

Glucotrack, Inc. Announces Closing of $10.0 Million Public Offering and Concurrent Private Placement Converting $4.0 in Outstanding Debt

PSM_EmpowerTrading
PSM_EmpowerTrading Aug. 31 at 3:24 AM
🌅 Watchlist part 2 ✅ $WETO low 7 support, above 7.20, potential to 8/8.70 🔄 $VBIO 1/25 reverse split (RS), new price ~3 🔄 $OMH 1/50 RS, new price ~3.50 🔄 $NXL 1/30 RS, new price ~7.50 🔄 $GCTK 1/15 RS, new price ~4.23 ✅ Ideal long entry near current support 🎯 Ideal stop loss below current support 🚨 Avoid chasing longs into strength near resistance 🎯🎯 Goal is GREEN 🤑🤑 not GREED 🥵🥵
0 · Reply
HMIC
HMIC Aug. 30 at 1:16 AM
$GCTK The Tutes will be jumping on board.
0 · Reply
BullishCandle
BullishCandle Aug. 29 at 10:57 PM
$GCTK $INHD Everyone is ignoring the best setup for next week. NCRA has the recipe to see a parabolic move. Market is slowly finding this low float gem. Has everything, Bullish DD/ low float/ and a strong close. If you like money, make sure to put NCRA on watch!
0 · Reply
PrimetimeVibes
PrimetimeVibes Aug. 29 at 6:30 AM
$NCRA What started as a strategic investment is becoming part of a much bigger story. 💎NCRA is advancing its transformation into Nocera Holdings, with a vision built around multiple high-growth technology markets spanning AI, digital infrastructure, robotics, biotech and digital assets. Parabolic potential here on NCRA, don't miss out. $SLGB $BTAI $SUGP $GCTK
0 · Reply
HMIC
HMIC Aug. 29 at 2:29 AM
$GCTK Looks like the price post split will be 4.20.
0 · Reply
focafoca99
focafoca99 Aug. 28 at 10:57 PM
$GCTK executed a 1-for-15 reverse stock split, consolidating shares and adjusting the share count.
0 · Reply
Adubstradesmini
Adubstradesmini Aug. 28 at 9:18 PM
$ARTL $CALC $CHGA $FTFT $GCTK
0 · Reply
itsStocksOver
itsStocksOver Aug. 28 at 8:45 PM
$GCTK buy orders at 0.21
0 · Reply
TwongStocks
TwongStocks Aug. 28 at 8:10 PM
Tracking a total of 10 stocks with reverse splits on Monday. Nine on NASDAQ and one on the NYSE American. Expect trading to halt at 7:50pm ET tonight and resume at 9:00am Monday morning. I'll have to split the summary into two parts. Part 1 of 2: $ARTL 1 for 9. Will reduce outstanding shares from approx 4.93m to approx 548k. $CALC 1 for 5. Will reduce outstanding shares from approx 34.5m to approx 6.9m. $CHGA 1 for 20. Will reduce outstanding shares from approx 21.1m to approx 1.05m. $FTFT 1 for 4. Will reduce outstanding shares from approx 32.31m to approx 8.08m. $GCTK 1 for 15. Will reduce outstanding shares from approx 11.97m to approx 798k.
0 · Reply
OG80
OG80 Aug. 28 at 4:16 PM
$GCTK liquidate me. holding. fuck em.
0 · Reply
RetiredOldGeezer
RetiredOldGeezer Aug. 28 at 1:06 PM
$GCTK What to do? Last day to exit before split - I am holding - would guess the bottom is $3 post split (.20 per share) - maybe the genius medicine men can focus on the tracking device and put the Hawaiian guys to reserving honey for their toast.
0 · Reply
CallMeMyBeer
CallMeMyBeer Aug. 28 at 12:54 AM
$GCTK 😂😂😂😂😂😂😂😂
0 · Reply
OG80
OG80 Aug. 27 at 8:08 PM
$GCTK they should make a dilution / rs tracker. id buy more. instead im stuck because im too stupid to sell.
1 · Reply
TwongStocks
TwongStocks Aug. 27 at 6:32 PM
$GCTK Equity Corporate Actions Alert #2026 - 616 Information Regarding the Reverse Stock Split and CUSIP Number Change for GlucoTrack, Inc. (GCTK) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-616 GlucoTrack, Inc. (GCTK) will effect a one-for-fifteen (1-15) reverse split of its Common Stock. The reverse stock split will become effective on Monday, August 31, 2026. In conjunction with the reverse split, the CUSIP number will change to 45824Q887.
0 · Reply
RetiredOldGeezer
RetiredOldGeezer Aug. 27 at 6:01 PM
$GCTK All the RS will do is insure the stock goes down more -problem with PHD's are they live based on books whereas the wall street sharks live by consuming naive thinkers for breakfast.
1 · Reply
AceofDubs
AceofDubs Aug. 27 at 4:27 PM
$GCTK RS came sooner than I expected, ouchie. This will be RS #5, maybe this time will be the charm...lol.
0 · Reply
RetiredOldGeezer
RetiredOldGeezer Aug. 27 at 2:00 PM
$GCTK Maybe the genius medicine men can discover garlic and give it a code name to pump up the stock
0 · Reply
itsStocksOver
itsStocksOver Aug. 27 at 1:57 PM
$GCTK rs too, this’ll go down to 0.2
0 · Reply
DARKP00L
DARKP00L Aug. 27 at 1:21 PM
$GCTK 08:23 on Aug. 27 2026 Glucotrack, Inc. Announces Reverse Stock Split #tradeideas
0 · Reply
OG80
OG80 Aug. 27 at 12:58 PM
$GCTK its over. rs this to death. if your share count is small forget ever getting to use this for options in the future.
1 · Reply
OG80
OG80 Aug. 27 at 12:21 PM
$GCTK disgusting this is aloud.
1 · Reply
RetiredOldGeezer
RetiredOldGeezer Aug. 26 at 9:57 PM
$GCTK Come on Mr. CEO - realease a real fluff PR so I can minimize my losses and forget I ever invested in this - I invested in testing products not some bee venom that has been used in various forms for over 100 years in the US. Seems like your value is 1 injection versus 15 - but is it a treatment that is supported by real doctors and reimbursed under insurance and Medicare? How about some news on your core products?
1 · Reply